首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16170篇
  免费   1418篇
  国内免费   7篇
  2022年   115篇
  2021年   221篇
  2020年   112篇
  2019年   180篇
  2018年   177篇
  2017年   139篇
  2016年   314篇
  2015年   560篇
  2014年   609篇
  2013年   862篇
  2012年   1016篇
  2011年   1019篇
  2010年   642篇
  2009年   608篇
  2008年   855篇
  2007年   873篇
  2006年   776篇
  2005年   831篇
  2004年   809篇
  2003年   757篇
  2002年   739篇
  2001年   170篇
  2000年   144篇
  1999年   180篇
  1998年   216篇
  1997年   132篇
  1996年   129篇
  1995年   116篇
  1994年   113篇
  1993年   110篇
  1992年   151篇
  1991年   131篇
  1990年   121篇
  1989年   102篇
  1988年   132篇
  1987年   122篇
  1986年   131篇
  1985年   119篇
  1984年   151篇
  1983年   126篇
  1982年   147篇
  1981年   165篇
  1980年   174篇
  1979年   139篇
  1978年   139篇
  1977年   135篇
  1976年   118篇
  1975年   116篇
  1974年   123篇
  1973年   86篇
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH1-34) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction osteogenesis. These studies have demonstrated that intermittent PTH1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH1-34 treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the appropriate patient population for PTH1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications) and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering.  相似文献   
2.
The Asian Tree Toad genus Pedostibes, as currently understood, exhibits a conspicuously disjunct distribution, posing several immediate questions relating to the biogeography and taxonomy of this poorly known group. The type species, P. tuberculosus and P. kempi, are known only from India, whereas P. hosii, P. rugosus, and P. everetti are restricted to Southeast Asia. Several studies have shown that these allopatric groups are polyphyletic, with the Indian Pedostibes embedded within a primarily South Asian clade of toads, containing the genera Adenomus, Xanthophryne, and Duttaphrynus. Southeast Asian Pedostibes on the other hand, are nested within a Southeast Asian clade, which is the sister lineage to the Southeast Asian river toad genus Phrynoidis. We demonstrate that Indian and Southeast Asian Pedostibes are not only allopatric and polyphyletic, but also exhibit significant differences in morphology and reproductive mode, indicating that the Southeast Asian species’ are not congeneric with the true Pedostibes of India. As a taxonomic solution, we describe a new genus, Rentapia gen. nov. to accommodate the Southeast Asian species.  相似文献   
3.
4.
5.
6.
7.
8.
The effect of a 30-day treatment with Madiol was studied on the activity of some enzymes, nucleic acids, protein and glycogen content of the liver of adult female rats and youngs born from mothers treated during pregnancy. Madiol caused a significant increase in SDH and Atp-ase activity, and decreased glycogen and acid phosphatase.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号